Publication Detail

Citation : Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, Harrison L, Morris E, Gross TG, Sanger W, Perkins S, Cairo MS. (2011)
Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report.
Br J Haematol 153(6):758-63.
Abstract : Children/adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL) have an excellent prognosis but relapses still occur. While chromosomal aberrations and/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect minimal disease (MD). Children/adolescents with intermediate-risk B-NHL were treated with French-British-American/Lymphome Malins de Burkitt 96 (FAB/LMB96) B4 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for MD. Initial specimens were screened for IGHV family usage with primer pools followed by individual primers to identify MD. Thirty-two diagnostic/staging specimens screened positive with primer pools and unique IGHV family primers were identified. Two patients relapsed; first relapse (4 months from diagnosis) was MD-positive at EOI, the second (36 months from diagnosis) was MD-positive at EOT. At EOI, recurrent rates were similar between the MRD-positive and MRD-negative patients (P = 0�·40). At EOT, only 13/32 patients had MRD data available with one relapse in the MRD-positive group and no recurrences in the MRD-negative group (P = 0�·077). The study demonstrated molecular-disseminated disease in which IgIGHV primer pools could be used to assess MD. This feasibility study supports future investigations to assess the validity and significance of MD screening in a larger cohort of patients with intermediate-risk mature B-NHL.
URL Link : http://www.ncbi.nlm.nih.gov/pubmed/21496005
PMID : 21496005
PMCID : PMC3103617
News
15 September 2017:
RCMI Conference Travel Support

We are currently encouraging scientists engaged in health disparities research, healthcare and public health professionals, public policy professional…

10 September 2017:
Call for Abstracts: RCMI Translational Science 2017 Conference

Call for Abstracts

Abstract Deadline Extended

Submit Your Abstracts

Abstract submission for oral and poster presentations is…

16 May 2017:
Robert Wood Johnson Funding Opportunity

If our nation is to make the opportunity for health available to all, we need leaders who will be able to meet the challenges before us – leade…


View more news...


Seminars & Events
16 June 2017, 9am - 10:30am:
HEALTH & MEDICINE SEMINAR - Kukulu Ola Hou
02 June 2017, 8:15am - 4:10pm:
PROMOTING EXCELLENCE IN CLINICAL RESEARCH
02 November 2016, 9am:
RMATRIX-II Collaboration Pilot Projects Program 2017 -- Informational Webinar

View more seminars & events...

Supported by a grant from the National Institute on Minority Health and Health Disparities (U54MD007584), National Institutes of Health.